Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review Publisher Pubmed



Etemadifar M¹ ; Nouri H^{2, 3} ; Sedaghat N^{2, 3} ; Ramezani A² ; Kargaran PK⁴ ; Salari M⁵ ; Kaveyee H² Show Affiliations
Source: Multiple Sclerosis and Related Disorders Published:2024

Abstract

Background: Pediatric-onset multiple sclerosis (POMS) cases, defined as multiple sclerosis (MS) with onset before the age of 18, represent between 3 and 5 % of all MS patients. Anti-CD20 drugs mainly rituximab, ocrelizumab, and ofatumumab are being widely used in adult-onset MS. Their use in POMS is also being increasingly considered by experts. Objective: to review the latest evidence on safety and efficacy of the use of anti-CD20 therapies in POMS. Methods: An extensive search was performed in PubMed, Scopus, and Web of Science databases until the end of July 1st, 2024. Two independent reviewers screened the articles, and collected data. 832 studies were screened using Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Results: 12 studies on rituximab (328 patients) and 6 studies on ocrelizumab (106 patients) were synthesized. Using monoclonal antibodies in POMS patients has a noteworthy effect on reducing relapses and lesions and achieving no evidence of disease activity especially in highly active POMS patients. However, anti-CD20 therapies in MS are associated with potential adverse events (AEs). Additional data is required on the effect of anti-CD20 therapy on disability accrual. Conclusion: Although anti-CD20 therapy is associated with some AEs, it can be provided in several circumstances, especially to patients with highly active disease, or ones resistant to platform therapies. © 2024 Elsevier B.V.